Doptelet® (avatrombopag) receives positive opinion from CHMP for treatment of ITP |
| December 11, 2020 | December 2020 Bond Updates |
|
STOCKHOLM, Dec. 11, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of Doptelet® (avatrombopag) for the treatment... |
| View more at: https://www.prnewswire.com:443/news-releases/doptelet-avatrombopag-receives-positive-opinion-from-chmp-for-treatment-of-itp-301191178.html |
| Related News |
|